Cargando…
Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus
The bacterial pathogens Streptococcus agalactiae (GBS) and Staphylococcus aureus (S. aureus) cause serious infections in humans and animals. The emergence of antibiotic-resistant isolates and bacterial biofilm formation entails the urge of novel treatment strategies. Recently, there is a profound sc...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473942/ https://www.ncbi.nlm.nih.gov/pubmed/34589067 http://dx.doi.org/10.3389/fmicb.2021.700605 |
_version_ | 1784575109222105088 |
---|---|
author | Asadpoor, Mostafa Ithakisiou, Georgia-Nefeli van Putten, Jos P. M. Pieters, Roland J. Folkerts, Gert Braber, Saskia |
author_facet | Asadpoor, Mostafa Ithakisiou, Georgia-Nefeli van Putten, Jos P. M. Pieters, Roland J. Folkerts, Gert Braber, Saskia |
author_sort | Asadpoor, Mostafa |
collection | PubMed |
description | The bacterial pathogens Streptococcus agalactiae (GBS) and Staphylococcus aureus (S. aureus) cause serious infections in humans and animals. The emergence of antibiotic-resistant isolates and bacterial biofilm formation entails the urge of novel treatment strategies. Recently, there is a profound scientific interest in the capabilities of non-digestible oligosaccharides as antimicrobial and anti-biofilm agents as well as adjuvants in antibiotic combination therapies. In this study, we investigated the potential of alginate oligosaccharides (AOS) and chitosan oligosaccharides (COS) as alternative for, or in combination with antibiotic treatment. AOS (2–16%) significantly decreased GBS V growth by determining the minimum inhibitory concentration. Both AOS (8 and 16%) and COS (2–16%) were able to prevent biofilm formation by S. aureus wood 46. A checkerboard biofilm formation assay demonstrated a synergistic effect of COS and clindamycin on the S. aureus biofilm formation, while AOS (2 and 4%) were found to sensitize GBS V to trimethoprim. In conclusion, AOS and COS affect the growth of GBS V and S. aureus wood 46 and can function as anti-biofilm agents. The promising effects of AOS and COS in combination with different antibiotics may offer new opportunities to combat antimicrobial resistance. |
format | Online Article Text |
id | pubmed-8473942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84739422021-09-28 Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus Asadpoor, Mostafa Ithakisiou, Georgia-Nefeli van Putten, Jos P. M. Pieters, Roland J. Folkerts, Gert Braber, Saskia Front Microbiol Microbiology The bacterial pathogens Streptococcus agalactiae (GBS) and Staphylococcus aureus (S. aureus) cause serious infections in humans and animals. The emergence of antibiotic-resistant isolates and bacterial biofilm formation entails the urge of novel treatment strategies. Recently, there is a profound scientific interest in the capabilities of non-digestible oligosaccharides as antimicrobial and anti-biofilm agents as well as adjuvants in antibiotic combination therapies. In this study, we investigated the potential of alginate oligosaccharides (AOS) and chitosan oligosaccharides (COS) as alternative for, or in combination with antibiotic treatment. AOS (2–16%) significantly decreased GBS V growth by determining the minimum inhibitory concentration. Both AOS (8 and 16%) and COS (2–16%) were able to prevent biofilm formation by S. aureus wood 46. A checkerboard biofilm formation assay demonstrated a synergistic effect of COS and clindamycin on the S. aureus biofilm formation, while AOS (2 and 4%) were found to sensitize GBS V to trimethoprim. In conclusion, AOS and COS affect the growth of GBS V and S. aureus wood 46 and can function as anti-biofilm agents. The promising effects of AOS and COS in combination with different antibiotics may offer new opportunities to combat antimicrobial resistance. Frontiers Media S.A. 2021-09-13 /pmc/articles/PMC8473942/ /pubmed/34589067 http://dx.doi.org/10.3389/fmicb.2021.700605 Text en Copyright © 2021 Asadpoor, Ithakisiou, van Putten, Pieters, Folkerts and Braber. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Asadpoor, Mostafa Ithakisiou, Georgia-Nefeli van Putten, Jos P. M. Pieters, Roland J. Folkerts, Gert Braber, Saskia Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus |
title | Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus
|
title_full | Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus
|
title_fullStr | Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus
|
title_full_unstemmed | Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus
|
title_short | Antimicrobial Activities of Alginate and Chitosan Oligosaccharides Against Staphylococcus aureus and Group B Streptococcus
|
title_sort | antimicrobial activities of alginate and chitosan oligosaccharides against staphylococcus aureus and group b streptococcus |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473942/ https://www.ncbi.nlm.nih.gov/pubmed/34589067 http://dx.doi.org/10.3389/fmicb.2021.700605 |
work_keys_str_mv | AT asadpoormostafa antimicrobialactivitiesofalginateandchitosanoligosaccharidesagainststaphylococcusaureusandgroupbstreptococcus AT ithakisiougeorgianefeli antimicrobialactivitiesofalginateandchitosanoligosaccharidesagainststaphylococcusaureusandgroupbstreptococcus AT vanputtenjospm antimicrobialactivitiesofalginateandchitosanoligosaccharidesagainststaphylococcusaureusandgroupbstreptococcus AT pietersrolandj antimicrobialactivitiesofalginateandchitosanoligosaccharidesagainststaphylococcusaureusandgroupbstreptococcus AT folkertsgert antimicrobialactivitiesofalginateandchitosanoligosaccharidesagainststaphylococcusaureusandgroupbstreptococcus AT brabersaskia antimicrobialactivitiesofalginateandchitosanoligosaccharidesagainststaphylococcusaureusandgroupbstreptococcus |